BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Zai Lab Back in the Game with Positive Ovarian Cancer Data

  Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.

  March 21, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Cortexyme, SQZ, Others Present New Insights into Alzheimer’s and Parkinson’s

  The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.

  March 21, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  First Therapy Approved for Marinus and Seizures Associated with CDD

  Ztalmy is Marinus’ oral suspension medication for patients ages two years and older who experience seizures linked with cyclin-dependent kinase-like 5 deficiency disorder.

  March 21, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  BMS Sues AstraZeneca for Patent Infringement, Guardant Health Responds to Illumina

  BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina’s intellectual property lawsuit.

  March 21, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  BMS’s Big March Continues with $1B Volastra Oncology Alliance

  Bristol Myers Squibb Company forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.

  March 21, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Vallon’s Anti-Abuse ADHD Drug Formulation Flunks Clinical Trial

  Vallon Pharmaceuticals announced that its Phase III SEAL trial of ADAIR for treatment of ADHD failed to hit its primary endpoint.

  March 21, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Pfizer Boss Earned $24.3 Million in 2021 and Other COVID-19 News

  Albert Bourla, Pfizer’s CEO, took home a salary of $1.69 million in 2021. To Pfizer, he’s undoubtedly worth it, having led the company to its COVID-19 vaccine success.

  March 21, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Countdown’s on as FDA Accepts BLA for Provention Bio’s Diabetes Delay Drug

  Provention Bio has announced that the FDA has accepted its biologics license application resubmission for teplizumab, a drug intended to delay clinical Type I Diabetes (T1D) in at-risk individuals.

  March 21, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Policy

  Russian Invasion Threatens Critical Ukraine Medicinal Chemistry Industry

  Russia’s continued assault on Ukraine threatens a supply of chemicals and compounds that drug researchers and developers use across the globe.

  March 21, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Positive Ovarian Cancer Results Not Enough for ImmunoGen Investors

  ImmunoGen shares inexplicably plunged 23% after the company announced positive Phase III results of its new ovarian cancer treatment.

  March 21, 2022

   · 

  3 min read

   · 

  Mark Terry